Aileron, Roche in stapled peptide deal

Aileron Therapeutics Inc. (Cambridge, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to discover, develop and commercialize therapeutics against up to five undisclosed targets using Aileron's Stapled Peptide technology. The therapeutics will be developed for multiple therapeutic areas, including cancer, virology, inflammation, metabolism and CNS indications. Aileron will be responsible for the majority of discovery and preclinical testing, while Roche will be primarily responsible for further development. Aileron will receive at least $25 million in technology access fees and R&D support and is eligible for $1.1 billion in milestones, plus royalties. ...